From PharmExec.com:
April 7, 2011 — In the April 5
issue of PharmExec.com, the author raises the issue of whether Accountable Care Organizations (ACOs) will alter prescription drug business, and states that pharmaceutical companies hoping to do business with ACOs “will have to show that expensive brand drugs can offer not just better health outcomes, but also system-wide savings.” Coalition Executive Director John Kamp is quoted in the article, saying that drug marketers will need to become more sophisticated in “talking about the system economics of using specific new drugs.” cialis us
